Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Cloning And Mutagenesis Market Size Will Reach Over USD 9.29 Billion By 2030, at 18.7% CAGR Growth: Polaris Market Research

Published

on

New York, NY, Jan. 17, 2023 (GLOBE NEWSWIRE) — Polaris Market Research has published a new research report titled “Cloning and Mutagenesis Market Share, Size, Trends, Industry Analysis Report, By Product (Cloning Kits, Mutagenesis Kits); By Technology; By End-use; By Region; Segment Forecast, 2022 – 2030” in its research database.

“According to the latest research study, the global Cloning and Mutagenesis Market size & share are expected to generate revenue of USD 9.29 Billion By 2030 and are estimated to be valued at USD 2.00 billion in 2021, at a compound annual growth rate (CAGR) of 18.7% from 2022 to 2030”

What are Cloning And Mutagenesis? What is the Expected Size & Share of Cloning And Mutagenesis Market?

Cloning is the procedure of engineering the same organism, tissue, biological entity, or cell, either naturally or artificially. A biotechnology method is used to perform the artificial clone technology.  Mutagenesis is the process by which the DNA of an organism is permanently changed, resulting in the production of gene mutation. Mutagenesis is performed experimentally in laboratory procedures where mutations in the DNA are formed for the production of mutation of the genes.

Cloning and mutagenesis is the technique used to study the structure and functionality of proteins, developed to confirm the effect of mutations both in vitro and in vivo. The growing adoption of cloning and mutagenesis technologies, such as PCR, due to the increasing demand for personalized medicine, is expected to drive the cloning and mutagenesis market size. The rising prevalence of genetic abnormalities and chronic diseases is further anticipated to boost the growth of the market.

Request Sample Copy of Research Report @ https://www.polarismarketresearch.com/industry-analysis/cloning-and-mutagenesis-market/request-for-sample

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)

Our Sample Report May Includes:

  • 2030 Updated Report Introduction, Overview, and In-depth industry analysis.
  • 115+ Pages Research Report (Inclusion of Updated Research).
  • Provide Chapter-wise guidance on Request.
  • 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
  • Includes Updated List of tables & figures.
  • Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.

Some of the Top Market Players:

  • Agilent Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • New England Biolabs
  • Takara Bio Inc.
  • Merck KGaA
  • Promega Corporation
  • Bio-Rad Laboratories Inc.
  • Danaher
  • Jena Bioscience GmbH
  • Assay Genie
  • TransGen Biotech Co. Ltd

For Additional Information on Key Players, Download a PDF Brochure: https://www.polarismarketresearch.com/industry-analysis/cloning-and-mutagenesis-market/request-for-sample

Our Free Sample Report Includes

  • Report introduction, overview, and in-depth industry analysis
  • Breakdown data by regions, type, players, and applications
  • Competitive landscape and leading competitor market shares
  • 110+ pages research report
  • Offers chapter-wise instruction on request
  • Includes market presence across different geographies with share, size, and trends
  • Updated list of tables and figures
  • The report covers leading players with their business strategies
  • Factors and fact research methodology

Growth Driving Factors

  • Rising popularity of reproductive cloning is likely to push the market growth

An increasing number of innovations and novel product launches in the cloning and mutagenesis market are expected to propel market growth. The growing popularity of reproductive cloning is predicted to contribute to the cloning and mutagenesis industry growth during the forecast period. Other factors, such as the rising use of personalized drugs and a surge in cases of genetic disorders and diseases like cancer and HIV, are likely to flourish the market expansion. Growing investments in R&D by key manufacturers in genetic diseases fuel the market demand.

Moreover, the rising focus on protein engineering for therapeutic development is escalating the growth prospects for the market. Technological developments in cloning services, along with increased synergistic industry activities, augment the cloning and mutagenesis market sales. A surge in strategic collaborations among private as well as government organizations is an additional factor projected to accelerate the industry’s future growth.

Directly Purchase a copy of the report with TOC @ https://www.polarismarketresearch.com/checkouts/19211

Segmental Analysis

  • Rising applications of cloning kits to fuel the market growth: Based on product, the market has been bifurcated into cloning kits and mutagenesis kits. The cloning kits category led the market in 2021 because they are utilized in sectors like biopharmaceuticals, gene therapy, and gene analysis. Thus, the rising use of these kits in the biotechnology industry is expected to boost segment growth in the cloning and mutagenesis market over the foreseen period.
  • A number of benefits are offered by TOPO PCR cloning technology to boost industry growth: Based on technology, the market is segmented into TOPO PCR Cloning and site-directed mutagenesis. The TOPO PCR cloning segment accounted for the highest revenue share in the cloning and mutagenesis market in 2021 because it offers various benefits compared to conventional TA cloning, such as no ligation and restriction on cloning, no need for post-PCR steps, and greater efficiency.
  • Rising focus of pharma companies on drug discovery to fuel the market expansion: Based on end-use, the market is categorized into biopharmaceuticals and pharmaceutical companies and CROs and CMOS. Pharmaceutical and biopharmaceutical companies witnessed the largest revenue share in 2021. This growth can be attributed to the rise in the prevalence of diseases and the growing focus of pharmaceutical and biopharmaceutical businesses on discovering and developing drugs.

Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/cloning-and-mutagenesis-market/inquire-before-buying  

(Inquire about a report quote OR available discount offers to the sales team before purchase.)

Cloning And Mutagenesis Market Report Scope

Report Attribute Details
Revenue forecast in 2030 USD 9.29 Billion
Market size value in 2022 USD 2.36 Billion
Expected CAGR Growth 18.7% from 2022 – 2030
Base Year 2022
Forecast Year 2022 – 2030
Top Market Players Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., New England Biolabs, Takara Bio Inc., Merck KGaA, Promega Corporation, Bio-Rad Laboratories, Inc., Danaher, Jena Bioscience GmbH, Assay Genie, TransGen Biotech Co., Ltd.
Segments Covered By product, By Technology, By End-use, By Region
Customization Options Customized purchase options are available to meet any research needs. Explore customized purchase options

Geographic Overview

  • The demand in North America is expected to witness significant growth

In terms of geography, cloning and mutagenesis market demand in North America dominated the market in 2021 owing to the growing demand for biotechnology methods. Increased adoption of platforms grounded on genomic and proteomic data, which has led to increasing the use of cloning and mutagenesis methods, is majorly driving the market growth in North America.

Moreover, the Asia Pacific is expected to grow at the highest rate because of the rising requirement for novel treatments in the region. Other factor supporting regional growth of the cloning and mutagenesis market includes growing investment by the government in R&D, a rapidly growing economy, and rising infrastructure development.

Browse the Detail Report “Cloning And Mutagenesis Market Share, Size, Trends, Industry Analysis Report, By Product (Cloning Kits, Mutagenesis Kits); By Technology; By End-use; By Region; Segment Forecast, 2022 – 2030” with in-depth TOC: https://www.polarismarketresearch.com/industry-analysis/cloning-and-mutagenesis-market    

For Additional Information OR Media Enquiry, Please Mail At: [email protected]

Recent Developments

  • The U.S. business Telesis Bio, Inc. stated in May 2021 that its BioXp technology now supports long fragment cloning. With the aid of this endeavor, researchers can create multivariant, error-corrected vectors and clone them into bespoke vectors hand-free overnight.

Frequently Asked Questions

  • Who are the crucial companies operating the market?
  • What are the major industry norms influencing the development of the industry?
  • Which is the most propelling country in the industry?
  • Which application or product type will obtain progressive development possibilities during the forecast period?
  • What is the expected growth rate of the market during the foreseen period?

Polaris Market Research has segmented the cloning and mutagenesis market report based on product, technology, end-user, and region:

By Product Outlook

  • Cloning Kits
  • Mutagenesis Kits

By Technology Outlook

  • TOPO PCR Cloning
  • Site-directed Mutagenesis

By End-Use Outlook

  • Biopharmaceuticals and pharmaceutical companies
  • CROs and CMOs

By Region Outlook

  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Browse More Related Reports:

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.

Contact:

Likhil G
30 Wall Street
8th Floor,
New York City, NY 10005,
United States
Phone: +1-929 297-9727
Email: [email protected]
Web: https://www.polarismarketresearch.com

Follow Us: LinkedIn twitter

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform

Published

on

xtalpi-unveils-xtalgazer:-a-comprehensive-ai-driven-polymorph-selection-platform

CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ — XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.

XtalGazer provides a total solution for delivering high-quality polymorph screening and selection methods to expedite drug development and mitigate risks. It represents a paradigm shift in solid-state research, moving from the traditional trial-and-error approach to a data-driven, design-led methodology. The platform provides an expansive suite of foundational tools to accelerate polymorph discovery, characterization, and selection process, empowering pharmaceutical companies to conduct thorough research with less active pharmaceutical ingredient (API) in shorter development cycles.
A key component of XtalGazer is XtalCSP, a crystal structure prediction platform to perform global searches of crystal structures for target molecules and the other optional components in the corresponding searching space, offering a deep insight into possible stable forms. Furthermore, crystallization strategy recommendations will provide AI-backed experimental design to help avoid human bias. XtalGazer also utilizes MicroED to rapidly elucidate crystal structures from powder samples, reducing the need for growing single crystals.
XtalPi’s launch of XtalGazer marks another significant step in the company’s ongoing exploration of solid-state research. From crystal structure prediction platforms being one of the first products to launch at XtalPi, to today’s comprehensive polymorph selection platform, XtalPi will keep fulfilling its promise to solving challenging problems in this space. XtalPi will continue to deliver faster, more accurate, and more comprehensive approaches to building an ecosystem for the R&D process in solid-state, pre-formulation and crystallization.
For more information about XtalPi, please visit www.xtalpi.com.
About XtalPi:
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Media Contact: Vivienne [email protected]
Logo – https://mma.prnewswire.com/media/632519/XtalPi_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-unveils-xtalgazer-a-comprehensive-ai-driven-polymorph-selection-platform-302102794.html

Continue Reading

Artificial Intelligence

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Published

on

icis-and-base-oil-news-announce-partnership-to-enhance-market-insights

LONDON, March 28, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market. This collaboration marks a significant milestone in the dissemination and exchange of critical market data and insights.

With more than two decades of journalism experience at Bloomberg, Reuters, and Argus Media, Iain Pocock brings unparalleled expertise to this partnership. His deep understanding of illiquid energy markets makes him a credible and influential figure in the industry. Since November 2023, Iain has been working closely with ICIS to share and exchange valuable data and insights, enhancing the services both platforms offer to the base oils and lubricants market.
Through the collaboration, Iain integrates ICIS’ extensive content and data resources in Base Oil News market coverage. In return, he contributes market insights to ICIS News, including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers. This exchange ensures that subscribers of both ICIS and Base Oil News have access to the most comprehensive, timely, and accurate market information, empowering them to make informed decisions.
“It’s a very exciting partnership – where we leverage each other’s strengths and provide actionable insights to our customers,” said Iain Pocock, Founder of Base Oil News. “The market is the winner.”
“As ICIS is already the world’s most trusted pricing benchmark for base oils, this collaboration with Iain Pocock and Base Oil News provides an even stronger and deeper service to our customers,” said Stephen Burns, Editorial Director at ICIS. “Iain’s expertise and extensive industry connections are invaluable, and we have established a fruitful partnership that benefits the market at large.”
For the latest insights from Iain Pocock on ICIS News, visit ICIS News.  
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, fertilizer and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of £64bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64bn | €75bn | $81bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/icis-and-base-oil-news-announce-partnership-to-enhance-market-insights-302102782.html

Continue Reading

Artificial Intelligence

Trianz Welcomes Israel Abraham as Vice President of Services for Extrica.ai – The Data to AI Platform

Published

on

trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extrica.ai-–-the-data-to-ai-platform

SANTA CLARA, Calif., March 28, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Israel Abraham as Vice President of Extrica Platform Services.

Trianz has embarked on a transformative journey, redefining its value proposition with an ‘IP Led’ model, with a commitment to deliver the fastest time to value, lowest human dependence, and highest ROI. Central to this approach are our hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace.
Israel Abraham is a very well-known pioneer and industry leader in AI, data management, and analytics systems, with over three decades of experience. He joins as the services leader for Extrica- the Trianz Data to AI platform, which productizes data, provides data a face and purpose, and accelerates time to insights and AI by 50% or more. In the role of Extrica Services leader, Israel will lead the shaping, visioning, and delivery of Extrica.ai based enterprise wide datamesh, BI, and AI solutions for customers worldwide.
“We are thrilled to welcome Israel Abraham to the Trianz family,” said Sri Manchala, CEO of Trianz and author of Crossing the Digital Faultline. “He is a leader in modernization as well as conceptualization of data platforms anew. Israel’s prior background in the industry with financial services and insurance giants underscores our commitment to securing top-tier talent that brings real-world experiences and needs to our technology platforms. As we continue to broaden our footprint in the digital transformation space, Israel’s visionary leadership and practical experience will serve as the cornerstone in accelerating insights and AI to deliver transformative value to our clients.”
Having played pivotal roles in highly reputed and large organizations such as Liberty Mutual Insurance, MassMutual, Safeco, and CNA Insurance, Israel has garnered recognition as a seasoned leader in big data and AI cloud implementations. His accolades include the prestigious 2014 Ventana Research IT Innovation Award, the 2009 Informatica MDM Innovation Award, and three filed Data Engineering patents in the last four years.
“Trianz has been at the forefront of digital innovation, and Extrica.ai is a paradigm shifting data to AI platform that completely changes how analytics and AI are delivered- much faster, taking business ahead of change. I am excited to scale the adoption of the Extrica platform, which has attracted attention from giants across the industry and hyperscalers,” said Israel Abraham. “I look forward to engaging with customers, bringing my own experiences, and collaborating with the talented team at Trianz to further enhance the capabilities of the Extrica Platform Services to transform data & AI strategies, execution, and outcomes for customers.”
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our ‘IP Led Transformations’ approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media [email protected] +1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extricaai–the-data-to-ai-platform-302102589.html

Continue Reading
Advertisement

Latest News

Trending